Charles Schwab Investment Management Inc. Reduces Stock Holdings in Gossamer Bio, Inc. (NASDAQ:GOSS)

Charles Schwab Investment Management Inc. cut its position in shares of Gossamer Bio, Inc. (NASDAQ:GOSS) by 2.7% during the third quarter, Holdings Channel.com reports. The firm owned 1,228,077 shares of the company’s stock after selling 33,520 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Gossamer Bio were worth $1,211,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Sequoia Financial Advisors LLC raised its position in shares of Gossamer Bio by 26.7% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 118,500 shares of the company’s stock valued at $117,000 after buying an additional 25,000 shares during the period. Financial Advocates Investment Management raised its position in Gossamer Bio by 57.5% in the second quarter. Financial Advocates Investment Management now owns 106,850 shares of the company’s stock valued at $96,000 after purchasing an additional 39,000 shares during the period. US Bancorp DE acquired a new position in shares of Gossamer Bio in the 3rd quarter valued at $39,000. Choreo LLC purchased a new position in shares of Gossamer Bio during the 2nd quarter worth $46,000. Finally, GSA Capital Partners LLP acquired a new stake in shares of Gossamer Bio during the 3rd quarter worth about $67,000. 81.23% of the stock is currently owned by institutional investors and hedge funds.

Gossamer Bio Trading Up 1.7 %

GOSS opened at $0.87 on Wednesday. Gossamer Bio, Inc. has a 52 week low of $0.50 and a 52 week high of $1.60. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 3.64. The business has a fifty day simple moving average of $0.84 and a 200-day simple moving average of $0.87. The firm has a market cap of $197.71 million, a P/E ratio of -2.73 and a beta of 1.85.

Gossamer Bio (NASDAQ:GOSS) last posted its earnings results on Thursday, November 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.04. The firm had revenue of $9.48 million for the quarter, compared to analyst estimates of $4.52 million. On average, equities analysts expect that Gossamer Bio, Inc. will post -0.28 earnings per share for the current year.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Gossamer Bio in a research report on Monday, November 11th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Gossamer Bio presently has an average rating of “Buy” and an average price target of $9.20.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.